# De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

> **NCT06001320** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Virginia Commonwealth University** · enrollment: 30 (actual)

## Conditions studied

- Kidney Transplant; Complications
- CMV

## Interventions

- **DRUG:** Letermovir 480 mg once daily
- **OTHER:** Historical/Control

## Key facts

- **NCT ID:** NCT06001320
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-25
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06001320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06001320, "De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06001320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*